Journal of Medical Academics

Register      Login

VOLUME 4 , ISSUE 2 ( July-December, 2021 ) > List of Articles


KRAS Association with Lung Cancer: An Overview

Panav Rustagi, Shaifaly M Rustagi

Citation Information : Rustagi P, Rustagi SM. KRAS Association with Lung Cancer: An Overview. Journal of Medical Academics 2021; 4 (2):33-35.

DOI: 10.5005/jp-journals-11003-0110

License: CC BY-NC 4.0

Published Online: 22-10-2022

Copyright Statement:  Copyright © 2021; The Author(s).


PDF Share
  1. Jancik S, Drabek J, Radzioch D, et al. Clinical relevance of KRAS in human cancers. J Biomed Biotechnol 2010;2010:150960. DOI: 10.1155/2010/150960
  2. Tsuchida N, Murugan AK, Grieco M. Kirsten Ras oncogene: significance of its discovery in human cancer research. Oncotarget 2016;7(29):46717–46733. DOI: 10.18632/oncotarget.8773
  3. Westcott PM, To MD. The genetics and biology of KRAS in lung cancer. Chin J Cancer 2013;32(2):63–70. DOI: 10.5732/cjc.012.10098
  4. Ferrer I, Zugazagoitia J, Herbertz S, et al. KRAS-mutant non-small cell lung cancer: from biology to therapy. Lung Cancer 2018;124:53–64. DOI: 10.1016/j.lungcan.2018.07.013
  5. Soulieres D, Greer W, Magliocco AM, et al. KRAS mutation testing in the treatment of metastatic colorectal cancer with anti-EGFR therapies. Curr Oncol 2010;17(1):S31–S40. DOI: 10.3747/co.v17is1.614
  6. Sznol M, Hodi FS, Margolin K, et al. Phase I study of BMS-663513, a fully human anti-CD137 agonist monoclonal antibody, in patients (pts) with advanced cancer (CA). J Clin Oncology 2008;26(15):3007. DOI: 10.1200/jco.2008.26.15_suppl.3007
  7. Moll HP, Pranz K, Musteanu M, et al. Afatinib restrains K-RAS-driven lung tumorigenesis. Sci Transl Med 2018;10(446):eaao2301. DOI: 10.1126/scitranslmed.aao2301
  8. Yang H, Liang SQ, Xu D, et al. HSP90/AXL/eIF4E-regulated unfolded protein response as an acquired vulnerability in drug-resistant KRAS-mutant lung cancer. Oncogenesis 2019;8:45. DOI: 10.1038/s41389-019-0158-7
  9. Zhou H, Dai Y, Zhu L, et al. Poor response to platinum-based chemotherapy is associated with KRAS mutation and concomitant low expression of BRAC1 and TYMS in NSCLC. J Int Med Res 2016;44(1):89–98. DOI: 10.1177/0300060515607383
  10. Tian T, Li X, Zhang J. mTOR signaling in cancer and mTOR inhibitors in solid tumor targeting therapy. Int J Mol Sci 2019;20(3):755. DOI: 10.3390/ijms20030755
  11. Garon EB, Finn RS, Hamidi H, et al. The HSP90 inhibitor NVP-AUY922 potently inhibits non-small cell lung cancer growth. Mol Cancer Ther 2013;12(6):890–900. DOI: 10.1158/1535-7163.MCT-12-0998
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.